MCID: SGN002
MIFTS: 46

Signet Ring Cell Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Signet Ring Cell Adenocarcinoma

MalaCards integrated aliases for Signet Ring Cell Adenocarcinoma:

Name: Signet Ring Cell Adenocarcinoma 12 15
Carcinoma, Signet Ring Cell 44 70
Signet Ring Cell Carcinoma 12 17
Carcinoma Signet Ring Cell 54
Signet Ring Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3493
MeSH 44 D018279
NCIt 50 C3774
SNOMED-CT 67 189701002
UMLS 70 C0206696

Summaries for Signet Ring Cell Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which have signet ring appearance.

MalaCards based summary : Signet Ring Cell Adenocarcinoma, also known as carcinoma, signet ring cell, is related to gastric signet ring cell adenocarcinoma and gallbladder signet ring cell adenocarcinoma. An important gene associated with Signet Ring Cell Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Irinotecan and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include colon, prostate and lymph node, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Wikipedia : 73 Signet ring cell carcinoma (SRCC) is a rare form of highly malignant adenocarcinoma that produces mucin.... more...

Related Diseases for Signet Ring Cell Adenocarcinoma

Diseases related to Signet Ring Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 644)
# Related Disease Score Top Affiliating Genes
1 gastric signet ring cell adenocarcinoma 33.1 PIP KRT7 CDX2
2 gallbladder signet ring cell adenocarcinoma 32.8 MUC1 KRT7 CDH1
3 rectum signet ring adenocarcinoma 32.5 MLH1 CEACAM5
4 krukenberg carcinoma 32.5 KRT7 KRT20 CEACAM5 CDX2
5 pancreatic signet ring cell adenocarcinoma 32.2 TP53 MUC5AC MUC1 KRAS HRAS
6 gastric cancer, hereditary diffuse 31.6 TP53 PDPN MUC6 MLH1 KRAS CDH1
7 urachal adenocarcinoma 31.0 KRAS CEACAM5
8 cystitis cystica 30.7 KRT7 KRT20 CDX2
9 bile duct cysts 30.7 KRT7 KRAS HRAS CEACAM5
10 bladder adenocarcinoma 30.7 KRT7 KRT20 ERBB2 CDX2
11 thymus adenocarcinoma 30.7 KRT20 CEACAM5 CDX2
12 ampulla of vater benign neoplasm 30.7 KRAS HRAS CHGA
13 meckel diverticulum 30.7 KRT7 CHGA CDX2
14 linitis plastica 30.7 PIP KRT7 KRT20 ERBB2 CEACAM5 CDX2
15 gallbladder adenocarcinoma 30.6 TP53 KRT20 ERBB2
16 rectum cancer 30.6 MLH1 KRT20 KRAS HRAS CEACAM5
17 clear cell adenocarcinoma 30.6 TP53 KRT7 KRT20
18 peptic ulcer disease 30.6 TP53 MUC5AC HRAS
19 neuroendocrine tumor 30.6 KRT20 HRAS CHGA CDX2
20 squamous cell papilloma 30.6 TP53 HRAS
21 eyelid carcinoma 30.6 PIP KRT7 KRT20
22 appendix adenocarcinoma 30.6 KRT7 KRT20 KRAS HRAS CHGA CDX2
23 endodermal sinus tumor 30.6 KRT7 CHGA CEACAM5
24 secretory meningioma 30.6 MUC1 KRT7 CEACAM5
25 intestinal obstruction 30.5 KRT7 KRT20 CEACAM5 CDX2
26 acute cholangitis 30.5 MUC5AC MUC1 CEACAM5
27 cystitis 30.5 TP53 KRT7 KRT20 CDH1
28 exanthem 30.5 KRAS HRAS ERBB2
29 neuroendocrine carcinoma 30.5 MUC1 KRT7 KRT20 CHGA CEACAM5 CDH1
30 gastrointestinal carcinoma 30.4 TP53 MUC1 KRT20 CEACAM5 CDX2
31 pleomorphic carcinoma 30.4 TP53 PDPN KRT7
32 chromophobe renal cell carcinoma 30.4 MUC1 KRT7 KRT20 CHGA
33 large cell neuroendocrine carcinoma 30.4 KRT7 KRT20 ERBB2 CHGA
34 adenosquamous carcinoma 30.4 TP53 MUC1 KRT7 KRAS CEACAM5
35 papilloma 30.4 TP53 KRT7 KRT20 KRAS ERBB2
36 benign mesothelioma 30.4 PDPN KRT7 KRT20 CEACAM5
37 apocrine adenocarcinoma 30.3 PIP MUC1 KRT7 ERBB2
38 renal cell carcinoma, nonpapillary 30.3 TP53 MUC1 KRT7 KRT20 HRAS CDH1
39 granulosa cell tumor of the ovary 30.3 TP53 KRT7 ERBB2 CHGA
40 solid adenocarcinoma with mucin production 30.3 MUC6 MUC5AC MUC1 KRT7 CHGA
41 paget disease, extramammary 30.2 PIP MUC1 KRT7 KRT20 ERBB2 CEACAM5
42 gastritis 30.2 TP53 MUC6 CHGA CDX2 CDH1
43 gastrointestinal stromal tumor 30.2 TP53 KRAS ERBB2 CHGA CDH1
44 papillary carcinoma 30.2 MUC1 KRT7 KRT20 ERBB2 CHGA CDH1
45 sweat gland cancer 30.2 TP53 PIP KRT7 KRT20 ERBB2 CEACAM5
46 tubular adenocarcinoma 30.2 MUC5AC MUC2 MUC1 KRT7 KRT20 ERBB2
47 merkel cell carcinoma 30.2 TP53 MUC1 KRT7 KRT20 CHGA
48 cholecystitis 30.2 TP53 MUC6 MUC5AC MUC1 CDH1
49 glandular cystitis 30.1 TP53 MUC5AC MUC1 KRT7 KRT20 CDX2
50 teratoma 30.1 TP53 KRT7 KRT20 KRAS CHGA CEACAM5

Graphical network of the top 20 diseases related to Signet Ring Cell Adenocarcinoma:



Diseases related to Signet Ring Cell Adenocarcinoma

Symptoms & Phenotypes for Signet Ring Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ARFIP2 CDH1 CHGA HRAS KRAS KRT7

MGI Mouse Phenotypes related to Signet Ring Cell Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ARFIP2 CDH1 CDX2 CHGA ERBB2 HRAS
2 digestive/alimentary MP:0005381 9.9 CDH1 CDX2 ERBB2 HRAS KRAS MLH1
3 endocrine/exocrine gland MP:0005379 9.7 CDH1 CDX2 CHGA ERBB2 HRAS KRAS
4 neoplasm MP:0002006 9.28 CDH1 CDX2 ERBB2 HRAS KRAS MLH1

Drugs & Therapeutics for Signet Ring Cell Adenocarcinoma

Drugs for Signet Ring Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
2
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
3
Fluorouracil Approved Phase 3 51-21-8 3385
4
leucovorin Approved Phase 3 58-05-9 6006
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
7
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9
Camptothecin Experimental Phase 3 7689-03-4
10 topoisomerase I inhibitors Phase 3
11 Tetrahydrofolates Phase 3
12 Formyltetrahydrofolates Phase 3
13 Immunoglobulins, Intravenous Phase 3
14 Antineoplastic Agents, Immunological Phase 3
15 Immunologic Factors Phase 3
16 Antibodies Phase 3
17 Immunoglobulins Phase 3
18 Antibodies, Monoclonal Phase 3
19 Vitamin B9 Phase 3
20 Nutrients Phase 3
21 Micronutrients Phase 3
22 Trace Elements Phase 3
23 Folate Phase 3
24 Vitamin B Complex Phase 3
25 Vitamins Phase 3
26 Immunosuppressive Agents Phase 3
27 Antidotes Phase 3
28 Calcium, Dietary Phase 3
29 Protective Agents Phase 3
30 Angiogenesis Inhibitors Phase 3
31 Cola Phase 3
32 Hematinics Phase 3
33 Immunoglobulin G Phase 3
34 Mitogens Phase 3
35 Endothelial Growth Factors Phase 3
36 Hormones Phase 3
37 Protein Kinase Inhibitors Phase 3
38
Apatinib Phase 3 811803-05-1
39 Antimetabolites Phase 3
40
Calcium Nutraceutical Phase 3 7440-70-2 271
41
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
42
nivolumab Approved Phase 2 946414-94-4
43
Turmeric Approved, Experimental, Investigational Phase 2
44
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
45 Analgesics, Non-Narcotic Phase 2
46 Antirheumatic Agents Phase 2
47 Turmeric extract Phase 2
48 Analgesics Phase 2
49 Anti-Inflammatory Agents Phase 2
50 Anti-Inflammatory Agents, Non-Steroidal Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
2 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
3 A Randomized, Multicenter, Controlled Study of XELOX (Oxaliplatin With Capecitabine) Combined With Apatinib Versus XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma With D2 Dissection. Not yet recruiting NCT03355612 Phase 3 Apatinib;XELOX
4 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
5 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
6 A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer Active, not recruiting NCT00745134 Phase 2 Capecitabine
7 Phase 1 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors Recruiting NCT03476681 Phase 1 NEO-201
8 Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer Terminated NCT01198535 Phase 1 Gamma-Secretase Inhibitor RO4929097
9 Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas? Completed NCT01249859

Search NIH Clinical Center for Signet Ring Cell Adenocarcinoma

Cochrane evidence based reviews: carcinoma, signet ring cell

Genetic Tests for Signet Ring Cell Adenocarcinoma

Anatomical Context for Signet Ring Cell Adenocarcinoma

MalaCards organs/tissues related to Signet Ring Cell Adenocarcinoma:

40
Colon, Prostate, Lymph Node, Appendix, Cervix, Bone Marrow, Skin

Publications for Signet Ring Cell Adenocarcinoma

Articles related to Signet Ring Cell Adenocarcinoma:

(show top 50) (show all 1815)
# Title Authors PMID Year
1
Chromogranin A expression correlates with tumour cell type and prognosis in signet ring cell carcinoma of the stomach. 54 61
18269581 2008
2
Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. 61 54
16948518 2006
3
Primary cutaneous signet ring cell carcinoma expressing cytokeratin 20 immunoreactivity. 61 54
16488312 2006
4
Dynamic alteration of the E-cadherin/catenin complex during cell differentiation and invasion of undifferentiated-type gastric carcinomas. 54 61
15682444 2005
5
Molecular characteristics of eight gastric cancer cell lines established in Japan. 54 61
11107048 2000
6
The role of cytokeratins 20 and 7 and estrogen receptor analysis in separation of metastatic lobular carcinoma of the breast and metastatic signet ring cell carcinoma of the gastrointestinal tract. 61 54
11028811 2000
7
Gastric metastasis of mammary signet ring cell carcinoma--a differential diagnosis with primary gastric signet ring cell carcinoma. 54 61
9250925 1997
8
A case of small cell carcinoma of the stomach. 61 54
9058136 1997
9
E-cadherin gene mutations in signet ring cell carcinoma of the stomach. 54 61
8797891 1996
10
Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. 54 61
8640661 1996
11
Investigation of clinicopathological characters and gene expression features in colorectal signet-ring cell carcinoma utilizing CMS classification. 61
33767867 2021
12
[An unusually painful leg ulcer in an 81-year-old patient: an interdisciplinary challenge]. 61
33284357 2021
13
A case of signet ring cell carcinoma and mucosa-associated lymphoid tissue lymphoma of the stomach diagnosed simultaneously via magnifying endoscopy with narrow-band imaging. 61
33389693 2021
14
Colorectal cancer under 20 years old: a retrospective analysis from three tertiary hospitals. 61
32968876 2021
15
Poorly differentiated is more significant than signet ring cell component for lymph node metastasis in mixed-type early gastric cancer: a retrospective study from a large-volume hospital. 61
32277355 2021
16
Primary signet-ring cell carcinoma of the lung in an HIV-positive patient. 61
33594833 2021
17
Signet Ring Cell Gastric Carcinoma: Clinical Epidemiology and Outcomes in a Predominantly Latino County Hospital Population. 61
32448921 2021
18
Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. 61
33724653 2021
19
Signet ring cell carcinoma of rectum metastasizing to synchronous renal cell carcinoma: a case report. 61
33731191 2021
20
Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-center, randomized trial. 61
32679601 2021
21
Perforating duodenal ulcer with umbilical herniation as a metastatic complication of primary signet ring cell carcinoma of the breast. 61
33732425 2021
22
Adjuvant chemotherapy indications for stage I gastric cancer patients with negative lymph node. 61
33662780 2021
23
Conversion surgery for metastatic gastric cancer at 2 years after initial diagnosis of cancer of unknown primary with metastasis of cervical lymph nodes and ovary: a case report. 61
33665675 2021
24
Rectal MRI after neoadjuvant chemoradiation therapy: a pictorial guide to interpretation. 61
33651124 2021
25
Protein profiling reveals the characteristic changes of the complement cascade pathway in the tissues of gastric signet ring cell carcinoma. 61
33676000 2021
26
NK cells adjuvant therapy shows survival benefits in a gastric mixed signet ring cell carcinoma patient: A case report. 61
33725867 2021
27
Gastric linitis plastica due to signet-ring cell carcinoma with Krukenberg tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration. 61
33740238 2021
28
Salivary Mucinous Adenocarcinoma Is a Histologically Diverse Single Entity With Recurrent AKT1 E17K Mutations: Clinicopathologic and Molecular Characterization With Proposal for a Unified Classification. 61
33739781 2021
29
Characterization of Chronic Gastritis in Lynch Syndrome Patients With Gastric Adenocarcinoma. 61
33737995 2021
30
Wnt Signaling Shapes the Histologic Variation in Diffuse Gastric Cancer. 61
33217450 2021
31
Prognosis of interval distant metastases after neoadjuvant chemoradiotherapy for esophageal cancer. 61
33610543 2021
32
Histological characteristics, survival pattern and prognostic determinants among colorectal cancer patients in Ethiopia: A retrospective cohort study. 61
33718651 2021
33
Paratesticular tumors. A clinicopathological study from a single tertiary hospital in North India. 61
33189965 2021
34
Sarcoidosis Stage II: a Case Report and Review of the Literature. 61
33616320 2021
35
Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer. 61
33563277 2021
36
Enhanced endoscopic detection of occult gastric cancer in carriers of pathogenic CDH1 variants. 61
33206267 2021
37
Posterior reversible encephalopathy syndrome (PRES) caused by chemotherapy containing S-1 against diffuse type gastric cancer. 61
33009999 2021
38
Analysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan. 61
30999803 2021
39
Construction and validation a nomogram to predict overall survival for colorectal signet ring cell carcinoma. 61
33564088 2021
40
Widespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CT. 61
32804764 2021
41
Clinicopathological characteristics and survival in lung signet ring cell carcinoma: a population-based study. 61
33596400 2021
42
Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents. 61
33617508 2021
43
Is cardia cancer a special type of gastric cancer? A differential analysis of early cardia cancer and non-cardia cancer. 61
33758614 2021
44
Liver and Pancreatic Injury in Response to ALK Inhibitors in a Patient with Primary Signet Ring Cell Carcinoma of the Lung: A Case Report. 61
33776691 2021
45
A Rare Case of Primary Signet-Ring Cell Cervical Carcinoma: Early Stage with Independent Bilateral Ovarian Metastases. 61
33790573 2021
46
Primary Pancreatic Signet Ring Cell Carcinoma: A Case Report and Review of the Literature. 61
33569523 2021
47
Thirty-three long-term survivors after cytoreductive surgery in patients with peritoneal metastases from colorectal cancer: a retrospective descriptive study. 61
33509224 2021
48
Risk of Second Primary Malignancies Based on the Histological Subtypes of Colorectal Cancer. 61
33777813 2021
49
Does signet ring cell carcinoma component signify worse outcomes for patients with colorectal cancer? 61
32295719 2021
50
Gastric Collision Tumor of MALT Lymphoma and Signet Ring Cell Adenocarcinoma: a Rare Preoperative Diagnosis. 61
33400210 2021

Variations for Signet Ring Cell Adenocarcinoma

Expression for Signet Ring Cell Adenocarcinoma

Search GEO for disease gene expression data for Signet Ring Cell Adenocarcinoma.

Pathways for Signet Ring Cell Adenocarcinoma

Pathways related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TP53 SRC MUC6 MUC5AC MUC2 MUC1
2
Show member pathways
13.72 SRC MUC6 MUC5AC MUC2 MUC1 KRAS
3
Show member pathways
12.97 TP53 SRC KRAS HRAS CDH1 ARFIP2
4
Show member pathways
12.91 TP53 SRC MLH1 KRAS HRAS ARFIP2
5 12.81 TP53 MLH1 KRAS HRAS ERBB2 CDH1
6
Show member pathways
12.72 TP53 SRC KRAS HRAS ERBB2
7
Show member pathways
12.69 TP53 SRC MLH1 KRAS HRAS ERBB2
8
Show member pathways
12.64 TP53 SRC KRAS HRAS ERBB2 CDH1
9
Show member pathways
12.61 TP53 SRC KRAS HRAS ERBB2
10
Show member pathways
12.59 TP53 SRC KRAS HRAS ERBB2 CDH1
11
Show member pathways
12.57 TP53 SRC KRAS HRAS ERBB2
12 12.51 PDPN MUC1 KRT7 KRT20 CDH1
13
Show member pathways
12.49 TP53 MUC1 KRAS HRAS CDH1
14
Show member pathways
12.42 TP53 MUC2 MLH1 KRAS HRAS ERBB2
15
Show member pathways
12.33 SRC KRAS HRAS ERBB2 CDH1 ARFIP2
16
Show member pathways
12.31 TP53 SRC HRAS ERBB2
17 12.29 TP53 SRC KRAS HRAS
18
Show member pathways
12.29 TP53 SRC KRAS HRAS
19
Show member pathways
12.28 SRC KRAS HRAS ERBB2
20
Show member pathways
12.24 MUC6 MUC5AC MUC2 MUC1
21 12.23 TP53 SRC KRAS HRAS ERBB2
22
Show member pathways
12.22 SRC KRAS HRAS CEACAM5
23
Show member pathways
12.22 TP53 SRC KRAS HRAS ERBB2
24 12.17 SRC KRAS HRAS ERBB2
25
Show member pathways
12.1 MUC6 MUC5AC MUC2 MUC1
26
Show member pathways
12.1 SRC MUC1 KRAS HRAS ERBB2 CDH1
27 12.07 TP53 SRC MLH1 KRAS CDH1
28 12.01 SRC KRAS HRAS CDH1
29 12 TP53 SRC KRAS HRAS
30 11.95 TP53 KRAS HRAS ERBB2
31 11.92 TP53 SRC KRAS HRAS
32
Show member pathways
11.91 MUC6 MUC5AC MUC2 MUC1
33
Show member pathways
11.91 SRC MUC6 MUC5AC MUC2 MUC1 KRAS
34
Show member pathways
11.9 SRC KRAS HRAS ERBB2 ARFIP2
35 11.83 SRC KRAS HRAS
36 11.77 TP53 SRC KRAS
37 11.74 TP53 MLH1 ERBB2
38 11.72 SRC ERBB2 CDH1
39 11.69 TP53 HRAS ERBB2
40
Show member pathways
11.67 SRC KRAS HRAS
41 11.64 TP53 KRAS HRAS ERBB2
42 11.61 TP53 SRC KRAS HRAS
43 11.52 SRC KRAS HRAS
44 11.43 SRC KRAS HRAS ERBB2
45 11.27 HRAS ERBB2 CDH1
46 11.24 KRAS HRAS ERBB2
47 11.09 SRC KRAS HRAS
48 10.96 TP53 SRC KRAS HRAS ERBB2 CDH1
49 10.72 SRC KRAS HRAS

GO Terms for Signet Ring Cell Adenocarcinoma

Cellular components related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mucus layer GO:0070701 8.96 MUC5AC MUC2
2 Golgi lumen GO:0005796 8.92 MUC6 MUC5AC MUC2 MUC1

Biological processes related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.73 TP53 SRC PIP KRAS HRAS ERBB2
2 Ras protein signal transduction GO:0007265 9.63 TP53 KRAS HRAS
3 positive regulation of MAP kinase activity GO:0043406 9.46 SRC KRAS HRAS ERBB2
4 response to isolation stress GO:0035900 9.43 KRAS HRAS
5 entry of bacterium into host cell GO:0035635 9.4 SRC CDH1
6 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.37 TP53 MUC1
7 response to mineralocorticoid GO:0051385 9.32 SRC KRAS
8 O-glycan processing GO:0016266 9.26 MUC6 MUC5AC MUC2 MUC1
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.17 SRC MUC6 MUC5AC MUC2 MUC1 KRAS

Molecular functions related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 TP53 TMEM207 SRC PIP PDPN MUC6

Sources for Signet Ring Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....